These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 12700446

  • 21. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
    Mallon PW, Miller J, Kovacic JC, Kent-Hughes J, Norris R, Samaras K, Feneley MP, Cooper DA, Carr A.
    AIDS; 2006 Apr 24; 20(7):1003-10. PubMed ID: 16603852
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. A prospective study of body fat redistribution, lipid, and glucose parameters in HIV-infected patients initiating combination antiretroviral therapy.
    Walmsley S, Cheung AM, Fantus G, Gough K, Smaill F, Azad, Diong C, Raboud J.
    HIV Clin Trials; 2008 Apr 24; 9(5):314-23. PubMed ID: 18977720
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy.
    Cooper DA, Cordery DV, Reiss P, Henry K, Nelson M, O'Hearn M, Reynes J, Arastéh K, Chung J, Rowell L, Guimaraes D, Bertasso A, TORO 1 and TORO 2 Study Groups.
    HIV Med; 2011 Jan 24; 12(1):31-9. PubMed ID: 20497250
    [Abstract] [Full Text] [Related]

  • 28. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
    Tavassoli N, Bagheri H, Sommet A, Delpierre C, Marion-Latard F, Massip P, Aquilina C, Bonnet E, Obadia M, Labau E, Montastruc JL, Bernard J.
    Pharmacotherapy; 2006 Feb 24; 26(2):154-61. PubMed ID: 16466321
    [Abstract] [Full Text] [Related]

  • 29. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides.
    Dubé MP, Parker RA, Tebas P, Grinspoon SK, Zackin RA, Robbins GK, Roubenoff R, Shafer RW, Wininger DA, Meyer WA, Snyder SW, Mulligan K.
    AIDS; 2005 Nov 04; 19(16):1807-18. PubMed ID: 16227788
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Body shape and composition in HIV-infected women: an urban cohort.
    Karmon SL, Moore RD, Dobs AS, Keruly J, Barnett S, Cofrancesco J.
    HIV Med; 2005 Jul 04; 6(4):245-52. PubMed ID: 16011529
    [Abstract] [Full Text] [Related]

  • 32. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
    Carr A, Hudson J, Chuah J, Mallal S, Law M, Hoy J, Doong N, French M, Smith D, Cooper DA, PIILR Study Group.
    AIDS; 2001 Sep 28; 15(14):1811-22. PubMed ID: 11579243
    [Abstract] [Full Text] [Related]

  • 33. Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations.
    Gutiérrez F, Padilla S, Masiá M, Navarro A, Gallego J, Hernández I, Ramos JM, Martin-Hidalgo A.
    Antivir Ther; 2004 Feb 28; 9(1):105-13. PubMed ID: 15040542
    [Abstract] [Full Text] [Related]

  • 34. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy.
    Sutinen J, Häkkinen AM, Westerbacka J, Seppälä-Lindroos A, Vehkavaara S, Halavaara J, Järvinen A, Ristola M, Yki-Järvinen H.
    AIDS; 2002 Nov 08; 16(16):2183-93. PubMed ID: 12409740
    [Abstract] [Full Text] [Related]

  • 35. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA, Amin J, Mallon PW, Kumarasamy N, Lombaard J, Wood R, Chetchotisakd P, Phanuphak P, Mohapi L, Azwa I, Belloso WH, Molina JM, Hoy J, Moore CL, Emery S, Cooper DA, SECOND-LINE Study Group.
    Lancet HIV; 2017 Jan 08; 4(1):e13-e20. PubMed ID: 27815068
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Long-term body composition changes in antiretroviral-treated HIV-infected individuals.
    Grant PM, Kitch D, McComsey GA, Collier AC, Bartali B, Koletar SL, Erlandson KM, Lake JE, Yin MT, Melbourne K, Ha B, Brown TT.
    AIDS; 2016 Nov 28; 30(18):2805-2813. PubMed ID: 27662545
    [Abstract] [Full Text] [Related]

  • 40. [Corporal fat distribution and lipidic and glicemic profiles of HIV-infected patients].
    Guimarães MM, Greco DB, de O Júnior AR, Penido MG, Machado LJ.
    Arq Bras Endocrinol Metabol; 2007 Feb 28; 51(1):42-51. PubMed ID: 17435854
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.